The heart of a patient with type 1 diabetes

1. Soedamah- Muthu SS, Fuller JH, Mulnier HE et al. All‑cause mortality rates in patients with type 1 diabetes mellitus compared with a non‑diabetic population from the UK general practice research database, 1992– 1999. Diabetologia 2006; 49: 660– 666.

2. Libby P, Nathan DM, Abraham K et al. Report of the National Heart, Lung, and Blood Institute- National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. Circulation 2005; 111: 3489– 3493.

3. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis; epidemiology, pathophysiology, and management. JAMA 2002; 287: 2570– 2581.

4. Strong JP, Malcom GT, McMahan CA et al. Prevalence and extent of atherosclerosis in adolescents and young adults: implication for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA 1999; 281: 727– 735.

5. Orchard TJ, Costacou T, Kretowski A et al. Type 1 diabetes and coronary artery disease. Diabetes Care 2006; 29: 2528– 2538.

6. Pambianco G, Costacou T, Ellis D et al. The 30‑year natural history of type 1 diabetes complication: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes 2006; 55: 1463– 1469.

7. Dahl- Jørgensen K, Larsen JR, Hanssen KF. Atherosclerosis in childhood and adolescent type 1 diabetes: early disease, early treatment? Diabetologia 2005; 48: 1445– 1453.

8. Järvisalo MJ, Jartti J, Näntö- Salonen K et al. Increased aortic intima- media thickness: a marker of preclinical atherosclerosis in high‑risk children. Circulation 2001; 104: 2943– 2947.

9. Margeirsdottir HD, Larsen JR, Brunborg C et al. Norwegian Study Group for Childhood Diabetes. High prevalence of cardiovascular risk factors in children and adolescents with type 1 diabetes: a population‑based study. Diabetologia 2008; 51: 554– 561.

10. Schwab KO, Doerfer J, Hecker W et al. Spectrum and prevalence of atherogenic risk factors in 27,358 children, adolescents, and young adults with type 1 diabetes: cross- sectional data from the German diabetes documentation and quality management system (DPV). Diabetes Care 2006; 29: 218– 225.

11. Laing SP, Swerdlow AJ, Slater SD et al. Mortality from heart disease in cohort of 23 000 patients with insulin‑ treated diabetes. Diabetologia 2003; 46: 760– 765.

12. Larsen J, Brekke M, Sandvik L et al. Silent coronary atheromatosis in type 1 diabetic patients and its relation to long‑term glycemic control. Diabetes 2002; 51: 2637– 2641.

13. Pajunen P, Taskinen MR, Nieminen MS et al. Angiographic severity and extent of coronary disease in patients with type 1 diabetes mellitus. Am J Cardiol 2000; 86: 1080– 1085.

14. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long‑term complications in insulin‑dependent diabetes mellitus. N Engl J Med 1993; 329: 977– 986.

15. Nathan DM, Lachin J, Cleary P et al. Intensive diabetes therapy and carotid intima- media thickness in type 1 diabetes mellitus. N Engl J Med 2003; 348: 2294– 2303.

16. Nahtan DM, Cleary PA, Backlund JY et al. DCCT/ EDIC study research group. Intensive diabetes treatment and cardiovascular disease in patients with Type 1 Diabetes. N Engl J Med 2005; 353: 2643– 2653.

17. Larsen JR, Brekke M, Bergengen L et al. Mean HbA1c over 18 years predicts carotid intima media thickness in women with type 1 diabetes. Diabetologia 2005; 48: 776– 779.

18. Jensen- Urstad KJ, Reichard PG, Rosfors JS et al. Early atherosclerosis is retarded by improved long‑term blood glucose control in patients with IDDM. Diabetes 1996; 45: 1253– 1258.

19. Stettler C, Allemann S, Jüni P et al. Glycemic control and macrovascular disease in type 1 and 2 diabetes mellitus: meta‑analysis and of randomized trials. Am Heart J 2006; 152: 27– 38.

20. Orchard TJ, Olson JC, Erbey JR et al. Insulin resistance –  related factors but not glycemia, predict coronary artery disease in type 1 diabetes: 10 year follow‑up data from the Pittsburg Epidemiology of Diabetes Complication Study. Diabetes Care 2003; 26: 1374– 1379.

21. Prince CT, Becker DJ, Costacou T et al. Changes in glycaemic control and risk of coronary artery disease in type 1 diabetes mellitus: findings from the Pittsburgh Epidemiology of Diabetes Complications Study (EDC). Diabetologia 2007; 50: 2280– 2288.

22. Juutilainen A, Lehto S, Rönnemma T et al. Similarity of the impact of type 1 and type 2 diabetes on cardiovascular mortality in middle- aged subjects. Diabetes Care 2008; 31: 714– 719.

23. Orchard TJ, Stevens LK, Forrest KY et al. Cardiovascular disease in insulin dependent diabetes mellitus: similar rates but different risk factors in the US compared with Europe. Int J Epidemiol 1998; 27: 976– 983.

24. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114 (Suppl 2): 555– 576.

25. Erbey JR, Kuller LH, Becker DJ et al. The association between a family history of type 2 diabetes and coronary artery disease in a type 1 diabetes population. Diabetes Care 1998; 21: 610– 614.

26. Mäkimattila S, Ylitalo K, Schlenzka A et al. Family histories of Type II. diabetes and hypertension predict intima- media thickness in patients with Type I diabetes. Diabetologia 2002; 45: 711– 718.

27. Thorn LM, Forsblom C, Fagerudd J et al. FinnDiane Study Group. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (The FinnDiane study). Diabetes Care 2005; 28: 2019– 2024.

28. Kilpatrick ES, Rigby AS, Atkin SL. Insulin resistance, the metabolic syndrome and complication risk in type 1 diabetes. „Double diabetes“ in the Diabetes Control and Complications Trial. Diabetes Care 2007; 30: 707– 712.

29. Lloyd CE, Kuller LH, Ellis D et al. Coronary artery disease in IDDM. Gender differences in risk factors but not risk. Arterioscler Thromb Vasc Biol 1996; 16: 720– 726.

30. Taskinen MR. Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus. Diabetes 1992; 41 (Suppl 2): 12– 17.

31. Jenkins AJ, Lyons TJ, Zheng D et al. Serum lipoproteins in the diabetes control and complications trial/ epidemiology of diabetes intervention and complications cohort: association with gender and glycemia. Diabetes Care 2003; 26: 810– 818.

32. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135– 1143.

33. Groop PH, Thomas MC, Rosengård- Bärlund M et al. HDL composition predicts new‑onset cardiovascular disease in patients with type 1 diabetes. Diabetes Care 2007; 30: 2706– 2707.

34. Tuomilehto J, Borch- Johnsen K, Molarius A et al. Incidence of cardiovascular disease in Type 1 (insulin‑dependent) diabetic subjects with and without diabetic nephropathy in Finland. Diabetologia 1998; 41: 784– 790.

35. Torffvit O, Lövestam- Adrian M, Agardh E et al. Nephropathy, but not retinopathy is associated with the development of heart disease in type 1 diabetes: a 12‑year observation study of 462 patients. Diabet Med 2005; 22: 723– 729.

36. Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643– 2653.

37. Klausen K, Borch- Johnsen K, Feldt- Rasmussen B et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004; 110: 32– 35.

38. Whincup PH, Gilg JA, Emberson JR et al. Passive smoking and risk of coronary heart disease and stroke: prospective study with nicotine measurement. BMJ 2004; 329: 200– 205.

39. Robinson RT, Harris ND, Ireland RH et al. Changes in cardiac repolarization during clinical episodes of nocturnal hypoglycaemia in adults with Type 1 diabetes. Diabetologia 2004; 47: 312– 315.

40. Duh E, Feinglos M. Hypoglycemia‑induced angina pectoris in a patient with diabetes mellitus. Ann Intern Med 1994; 121: 945– 946.

41. Järvisalo MJ, Raitakari M, Toikka JO et al. Endothelial dysfunction and increased arterial intima- media thickness in children with type 1 diabetes. Circulation 2004; 109: 1750– 1755.

42. Haller MJ, Samyn M, Nichols WW et al. Radial artery tonometry demonstrates arterial stiffness in children with type 1 diabetes. Diabetes Care 2004; 27: 2911– 2917.

43. Dabelea D, Kinney G, Snell- Bergeon JK et al. Effect of type 1 diabetes on the gender difference in coronary artery calcification: a role for insulin resistance? The Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study. Diabetes 2003; 52: 2833– 2839.

44. Janowitz WR, Agatston AS, Kaplan G et al. Differences in prevalence and extent of coronary artery calcium detected by ultrafast computed tomography in asymptomatic men and women. Am J Cardiol 1993; 72: 247– 254.

45. Costacou T, Edmundowicz D, Prince C et al. Progression of coronary artery calcium in type 1 diabetes mellitus. Am J Cardiol 2007; 100: 1543– 1547.

46. Bax JJ, Young LH, Frye RL et al. Screening for coronary Artery disease in patients with diabetes. Diabetes Care 2007; 30: 2729– 2736.

47. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005; 28 (Suppl 1): S4– S36.

48. McGill HC Jr, McMahan CA. Starting earlier to prevent heart disease. JAMA 2003; 290: 2320– 2322.

49. Colwell JA. American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care 2003; 26 (Suppl 1): S87– S88.

50. Barclav L. American Diabetes Association revises diabetes guidelines. Medscape CME. Diabetes Care December 2009: ahead of pub; prepared for publication in January 2010.

51. Moy CS, Songer TJ, LaPorte RE et al. Insulin‑dependent diabetes mellitus, physical activity, and death. Am J Epidemiol 1993; 137: 74– 81.

52. Khan AS, McLoughney CR, Ahmed AB. The effect of metformin on blood glucose control in overweight patients with Type 1 diabetes. Diabet Med 2006; 23: 1079– 1084.

53. Nathan DM, Clary PA, Backlund JYC et al. Intensive diabetes treatment and cardiovascular disease in patients with 1 diabetes. N Engl J Med 2005; 353: 2643– 2653.

54. Charvát J. Ischemická choroba srdeční u diabetiků 1. typu. In: Perušičová J (ed). Diabetes mellitus 1. typu. Praha: Geum 2007: 483– 491.

55. Frye RL, August P, Brooks MM et al. BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009; 360: 2503– 2515.

56. Škrha J. Patofyziologie a patogeneze diabetické neuropatie. Vnitř Lék 2005; 51 (Suppl 1): S67– S72.

57. Lacigová S, Rušavý Z, Mindlová J et al. Žaludeční vyprazdňování u diabetiků. Vnitř Lék 2000; 46: 213– 217.

58. Ziegler D, Zentai CP, Perz S et al. Prediction of mortality using measures of cardiac autonomic dysfunction in the diabetic and nondiabetic population The MONICA/ KORA Augsburg Cohort Study. Diabetes Care 2008; 31: 556– 561.

59. Bell DS. Dead in bed syndrome –  a hypothesis. Diabetes Obes Metab 2006; 8: 261– 263.

60. Witte DR, Tesfaye S, Chaturvedi N et al. EURODIAB Prospective Complications Study Group (2005). Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus. Diabetologia 2005; 48: 164– 171.

61. Ziegler D, Dannehl K, Volksw D et al. Prevalence of cardiovascular autonomic dysfunction assessed by spectral analysis and standard tests of heart- rate variation in newly diagnosed IDDM patients. Diabetes Care 1992; 15: 908– 911.

62. Liao D, Carnethon M, Evans GW et al. Lower heart rate variability is associated with the development of coronary heart disease in individuals with diabetes: the atherosclerosis risk in communities (ARIC) study. Diabetes 2002; 51: 3524– 3531.

63. Lacigová S, Šafránek P, Čechurová D et al. Could we predict asymptomatic cardiovascular autonomic neuropathy in type 1 diabetic patients attending out- patients clinics? Wien Klin Wochenschr 2007; 119: 303– 308.

64. Sallinger J, Vychodil R, Novotný J et al. Telemetric computer- aided system for non‑invasive examination of heart rate variability, type VariaPulse TF3. In IEEE Proc Comput Cardiol 1995: 437– 440.

65. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the DCCT. Diabetologia 1998; 41: 416– 423.

66. Peterson AD, Rutledge BN, Cleary PA et al. The effect of intensive diabetes treatment on resting heart rate in type 1 diabetes: the Diabetes Control and Complication Trial/ Epidemiology of Diabetes Interventions and Complications study. Diabetes Care 2007; 30: 2107– 2112.

67. Lacigová S, Rušavý Z, Čechurová D et al. Autonomní neuropatie u diabetiků, léčebné možnosti. Vnitř Lék 2002; 48: 534– 541.

68. Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanism, and therapeutic implications. Endocr Rev 2004; 25: 543– 567.

69. Avogaro A, Vigili de Kreutzenberg S, Nedut C et al. Diabetic cardiomyopathy: a metabolic perspective. Am J Cardiol 2004; 93: 13A– 16A.

70. Rubler S, Dlugash J, Yuceoglu YZ et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972; 30: 595– 602.

71. Spirito P, Bellone P, Harris KM et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000; 342: 1778– 1785.

72. Kannel WB, McGee DL. Diabetes and cardiovascular disease: The Framingham study. JAMA 1979; 241: 2035– 2038.

73. Suys BE, Katier N, Roman RP et al. Female children and adolescents with Type 1 diabetes have more pronounced early echocardiographic signs of diabetic cardiomyopathy. Diabetes Care 2004; 27: 1947– 1953.

74. Young LH. Diastolic function and type 1 diabetes. Diabetes Care 2004; 27: 2081– 2083.

75. Watts GF, Marwick TH. Ventricular dysfunction in early diabetic heart disease: detection, mechanism and significance. Clin Sci 2003; 105: 537– 540.

76. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007; 115: 3213– 3222.

77. Dúbrava J. Diabetická kardiomyopatia. Vnitř Lék 2005; 51: 314– 319.

78. How to diagnose diastolic heart failure. Working group report. European Study Group on Diastolic Heart Failure. Eur Heart J 1998; 19: 990– 1003.

79. Palmieri V, Capaldo B, Russo C et al. Uncomplicated type 1 diabetes and preclinical left ventricular myocardial dysfunction: insights from echocardiography and exercise cardiac performance evaluation. Diabetes Res Clin Pract 2008; 79: 262– 268.

80. Marwick TH. Identification of diabetic cardiomyopathy with cardiac magnetic resonance imaging. Int J Cardiovasc Imaging 2006; 22: 91– 92.

81. Didangelos TP, Arsos GA, Karamitsos DT et al. Left ventricular systolic and diastolic function in normotensive type 1 diabetic patients with or without autonomic neuropathy. A radionuclide ventriculography study. Diabetes Care 2003; 26: 1955– 1960.

82. Lubien E, DeMaria A, Krishnaswamy P et al. Utility of B- natriuretic peptide in detecting diastolic dysfunction. Comparison with Doppler velocity recordings. Circulation 2002; 105: 595– 601.

83. Aepfelbacher FC, Yeon SB, Weinrauch LA et al. Improved glycemic control induces regression of left ventricular mass in patients with type 1 diabetes mellitus. Int J Cardiol 2004; 94: 47– 54.

84. Hradec J. Diastolické srdeční selhání. REMEDIA 2004; 14: 121– 125.

85. Lacigová S, Bartunek L, Cechurova Det al. Influence of cardiovascular autonomic neuropathy on atherogenesis and heart function in patients with type 1 diabetes. Diabetes Res Clin Pract 2009; 83: 26– 31.